T-CURX is a biopharmaceutical start-up company based in Würzburg and Munich, focusing on the development and commercialization of next-generation CAR-T cell therapies for cancer indications with high medical needs. The proprietary CAR-T technologies were developed in the laboratory of co-founder Prof. Michael Hudecek at the University Hospital Würzburg and involve a non-viral, transposon-based gene transfer of the CAR receptor into the patient’s autologous T cells. The non-viral production of CAR-T cells is a key unique selling point for a fast, cost-efficient, safe, and patient-centered manufacturing method, including the production of CAR-T cells directly at the patient’s bedside. In future, the liponanoparticle technology developed by T-CURX will also be used for the targeted administration of the genetic components. T-CURX utilises its innovative manufacturing approach to develop a clinical pipeline with novel targets for hematological and solid tumors. T-CURX’s technologies have already been validated in an academically initiated Phase I clinical study. The company’s first proprietary clinical program is ready for clinical trial submission by the end of the year.